Avadel Pharmaceuticals — Flamel Technologies — Investor Presentation (June 2016)
31 slides from Avadel Pharmaceuticals's investor presentation, Jun 7, 2016
Slide 1: June 2016 1
June 2016 1
Slide 2: Forward Looking Statements
June 2016 2 Forward Looking Statements This presentation may include "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward - looking, and the words "anticipate," "assume,"
Slide 3: Investment Highlights
June 2016 3 Investment Highlights Mission: Build a diversified specialty pharmaceutical company that controls 100% of its drug development and future • Profitable; strong cash flow & balance sheet – NO DEBT • $84.3 million cash flow from operations generated in 2015 • $160 million in cash and market
Slide 4: Corporate Transformation
June 2016 4 Corporate Transformation Established as drug delivery & formulation company 1990 2006 Coreg CR® using Micropump ® received FDA approval (GSK partnered product ) 2012 Flamel acquired Éclat Pharmaceuticals 2013 FDA approval for Bloxiverz ® 2014 FDA approval for Vazculep ® Sold manufacturin
Slide 5: 2016 Expectations
June 2016 5 2016 Expectations 1 UMD is Flamel’s Unapproved Marketed Drugs Strategy, which takes unapproved drugs through the FDA approval process. These products are not protected by IP and are subject to generic filers. Complete cross - border merger from France to Ireland Commence registration & d
Slide 6: Current Pipeline
June 2016 6 Ibuprofen / LiquiTime® Pain / Fever Guaifenesin / LiquiTime® Respiratory Drug/ Technology Indication Proof of Concept Pilot Phase III Under Review Approved Unapproved Marketed Drug # 4 Undisclosed Sodium oxybate/ Micropump ® Narcolepsy Hydromorphone / Trigger Lock™ Pain Exenatide/Medusa™
Slide 7: Sodium Oxybate Market Opportunity
June 2016 7 Xyrem® FY 2016 sales expected to be $1.095 - $1.130 billion Sodium Oxybate Market Opportunity * GlobalData & JAZZ’s 4Q’15 e a rnings call >~ 178 , 000 narcoleptic patients in U . S . * < 13,000 patients on treatment* Large untapped opportunity exists in narcolepsy patient population >150
Slide 8: Micropump Sodium Oxybate (FT218)
June 2016 8 Micropump ® Sodium Oxybate (F T218) * Xyrem prescribing information Micropump sodium oxybate studied in 40 healthy volunteers at 4.5 grams, 6 grams and 7.5 grams Results showed: Similar onset of action as Xyrem Slightly lower Cmax than Similar blood levels at hours 7 - 8 Sodium Oxybate :
Slide 9: Micropump Overview
June 2016 9 Micropump ® Overview Robust platform technology utilizing microparticles for the extended/delayed release of drugs in GI tract Micropump 1 st approved in 2006 in Coreg CR (carvedilol) 10 years – no generics Tailored release profile solves dosing problems related to PK profiles and drugs
Slide 10: Trigger Lock Hydromorphone (FT227)
June 2016 10 Independent study confirmed better extraction/recovery than Exalgo & Oxycontin Awaiting FDA feedback on next steps Studied in 30 healthy volunteers: 3 FT227 prototypes (fasted & fed) Results: 1 formulation bioequivalent to Jurnista © (fasted) both AUC & Cmax Selected formulation to adva
Slide 11: LiquiTime Platform Overview
June 2016 11 Overview • Extended release liquid oral suspension for more convenient and improved dosing with a focus on pediatric and geriatric markets • Exclusive U . S . rights licensed to Perrigo for the OTC drug market : development ongoing • Flexible capability allows for the combination of mul
Slide 12: Medusa Exenatide (FT228)
June 2016 12 FT228 Overview • Subcutaneous injection formulation of exenatide , a GLP - 1 (glucagon - like peptide – 1 ) for treatment of Type 2 diabetes • Interim Phase I human clinical data reported in December 2015 • PK profile compatible with a release over one week in humans • Data for phase 1
Slide 13: Marketed Products
June 2016 13 Marketed Products
Slide 14: Éclat Portfolio Products
June 2016 14 Éclat Portfolio Products * IMS data Bloxiverz ® (neostigmine methylsulfate injection) • Indication: Reverses neuromuscular blockades used in surgical procedures • 1 of 3 approved versions; ~ 4 million vials sold annually in the U.S. * Vazculep ® (phenylephrine hydrochloride injection) •
Slide 15: Pediatric Products
June 2016 15 Pediatric Products • Indication: Perennial allergic rhinitis in children 2 years of age and older • Patent protection through March 2029 • Rx antihistamine market size in U.S. ~ $110M • Indication: 2nd generation Cephalosporin covering a variety of common pathogens • For children as you
Slide 16: Strong Intellectual Property Platform
June 2016 16 Strong Intellectual Property Platform US Europe Micropump® July 2027 July 2023 LiquiTime® September 2025 April 2023 Trigger Lock™ April 2027 May 2026 (pending) Medusa™ June 2031 June 2027 (pending) Product US Karbinal ™ ER March 2029 AcipHex ® Sprinkle™ September 2016 Flexichamber ® Mar
Slide 17: Seasoned Senior Management
June 2016 17 Seasoned Senior Management Name Title Experience Michael S. Anderson Chief Executive Officer 40+ years Pharma Mike Kanan Senior Vice President and Chief Financial Officer 30+ years Financial Phillandas T. Thompson Senior Vice President, General Counsel 16+ years Legal Sandy Hatten Senio
Slide 18: Key Financial Metrics (Unaudited)
June 2016 18 Key Financial Metrics (Unaudited) Income Statement Metrics Three months ended March 31, 2016 2015 Revenue $ 36.2 $32.9 COGS (4.4) (3.6) R&D (5.4) (6.0) SG&A (9.5) (4.5) Acquisition Earn - Out Payments/Accruals (5.4) (6.0) Adj Op. Profit (Loss) * 11.5 12.8 Adj. Net Income (Loss) * 1.6 4.
Slide 19: Flamel Technologies Transformed
June 2016 19 Flamel Technologies Transformed • Strong financial condition - profitable with strong cash flow and balance sheet • Seven FDA approved products • Experienced management team • Robust pipeline with extensive IP protection Mission: To build a diversified specialty pharmaceutical company t
Slide 20: Appendix
June 2016 20 Appendix
Slide 21: Reconciliation of Non GAAP to GAAP Results
June 2016 21 Reconciliation of Non GAAP to GAAP Results
Slide 22: Reconciliation of Non GAAP to GAAP Results: Free Cash Flow
June 2016 22 Reconciliation of Non GAAP to GAAP Results Free Cash Flow Net cash provided by operating activities 22,498$ 25,275$ Less: Purchases of property and equipment (460) (234) Contingent consideration - Acquisition-related payments (8,014) (325) Contingent consideration - Financing-related pa
Slide 23: Diversified and Proven Drug Delivery Platforms
June 2016 23 Diversified and Proven Drug Delivery Platforms • Outstanding drug delivery platforms to tackle key challenges in the formulation, in various dosage forms (e . g . capsules, tablets, sachets or oral liquid suspensions ; or injectable for subcutaneous administration) of a broad range of d
Slide 24: Micropump Platform at a Glance
June 2016 24 Micropump® Platform a t a Glance • Extended/delayed - release of drugs in the GI tract • Precise pharmacokinetics of single or combination of drugs in various formats • Numerous Micropump® - based products successfully tested in human clinical trials Various dosage forms (tablet, capsul
Slide 25: Micropump Microparticles for Controlled/Modified Release
June 2016 25 • Microparticles are dispersed in the stomach and pass into the small intestine, after which each microparticle releases the drug at an adjustable rate and over an extended period of time (up to 24 hours) • Drug released at an adjustable rate controlled and/or delayed • Micropump® micro
Slide 26: LiquiTime Platform at a Glance
June 2016 26 LiquiTime® Platform at a Glance LiquiTime® is a novel, proprietary and innovative delivery platform allowing the stable L iquid and controlled release formulation of one or several combined drugs over Time LiquiTime® meets challenges faced in the treatment of pediatric and geriatric pat
Slide 27: LiquiTime for Extended-Release Liquid Suspension
June 2016 27 Each microparticle is individually coated and behaves as an independent micro reservoir Coating • controls diffusion • keeps its integrity • offers good resistance to stress LiquiTime® f or Extended - Release Liquid Suspension L iquid suspension contains small coated drug microparticles
Slide 28: Trigger Lock Platform at a Glance
June 2016 Trigger Lock™ is a proprietary and innovative delivery platform that enables the controlled release of opioid analgesics while deterring abuse x The sustained release Micropump ® - based microparticles are virtually impervious to crushing x Trigger Lock™ resists extraction attempts to prev
Slide 29: Trigger Lock for Abuse Deterrence
June 2016 29 1. Drug loaded Micropump ® microparticles Sustained Release (SR) microparticles individually polymer coated which are resistant to crushing 2. Viscosifying ingredient(s) To prevent abuse by injection after extraction in a small volume of solvent 3. Quenching ingredient(s) To prevent ext
Slide 30: Medusa Platform at a Glance
June 2016 30 Medusa Depot Solubilization and stabilization of drugs Applicable to a wide range of small molecules, peptide and protein drugs Safe, non - immunogenic and fully biodegradable Sustained delivery from 1 to 7 days in human Combination of several different drugs in the same formulation Bio
Slide 31: Medusa Depot for Injection
June 2016 31 Medusa ™ Depot for Injection COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + Vitamin E Polyglutamate chain Drug solution or powder Formulation by simple mixing in water Non - covalent association ( reversible hydrophobic and/or electrostatic interaction) of
Flamel Technologies — Investor Presentation (June 2016) on 6ix